Literature DB >> 9371631

Promonocytic U937 subclones expressing CD4 and CXCR4 are resistant to infection with and cell-to-cell fusion by T-cell-tropic human immunodeficiency virus type 1.

H Moriuchi1, M Moriuchi, J Arthos, J Hoxie, A S Fauci.   

Abstract

Different strains of human immunodeficiency virus type 1 (HIV-1) vary markedly in the ability to infect cells of the monocyte/macrophage (M/M) lineage. M/M are generally resistant to infection with T-cell-tropic (T-tropic) strains of HIV-1. Recently, the chemokine receptors CCR5 and CXCR4 were identified as cofactors for fusion/entry of macrophage- and T-tropic strains of HIV-1, respectively. To investigate the mechanisms of resistance of M/M to T-tropic HIV-1 infection, we examined a number of subclones of the U937 promonocytic cell line. We found that certain subclones of U937 (plus clones) could, while others (minus clones) could not, support replication of T-tropic strains of HIV-1. We demonstrate that (i) both minus and plus clones support HIV-1 replication when transfected with an infectious molecular cDNA clone of a T-tropic HIV-1; (ii) minus clones do not, but plus clones do, efficiently support fusion with cells expressing HIV-1 IIIB Env; (iii) both plus and minus clones (with the exception of one clone) express physiologically functional CXCR4 protein as well as CD4 on the cell surface; (iv) introduction of CXCR4 into the CXCR4-negative clone does not restore fusogenicity with or susceptibility to T-tropic HIV-1; and (v) a ligand (stromal cell-derived factor 1) for or a monoclonal antibody (12G5) to CXCR4 does not effectively inhibit HIV-mediated cell-to-cell fusion of U937 cells. These data indicate that resistance to T-tropic HIV-1 infection of U937 minus clones occurs at fusion/ entry events and that expression of functional CXCR4 and CD4 is not a sole determinant for susceptibility to T-tropic HIV-1 infection; furthermore, they suggest that other factors are positively or negatively involved in HIV-mediated cell-to-cell fusion in U937 promonocytic cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9371631      PMCID: PMC230275     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Identification of a major co-receptor for primary isolates of HIV-1.

Authors:  H Deng; R Liu; W Ellmeier; S Choe; D Unutmaz; M Burkhart; P Di Marzio; S Marmon; R E Sutton; C M Hill; C B Davis; S C Peiper; T J Schall; D R Littman; N R Landau
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

2.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.

Authors:  T Dragic; V Litwin; G P Allaway; S R Martin; Y Huang; K A Nagashima; C Cayanan; P J Maddon; R A Koup; J P Moore; W A Paxton
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

3.  HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor.

Authors:  Y Feng; C C Broder; P E Kennedy; E A Berger
Journal:  Science       Date:  1996-05-10       Impact factor: 47.728

4.  CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1.

Authors:  S L Kozak; E J Platt; N Madani; F E Ferro; K Peden; D Kabat
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

5.  Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes.

Authors:  M Loetscher; T Geiser; T O'Reilly; R Zwahlen; M Baggiolini; B Moser
Journal:  J Biol Chem       Date:  1994-01-07       Impact factor: 5.157

6.  Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation.

Authors:  O Nussbaum; C C Broder; E A Berger
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

7.  Varicella-zoster virus (VZV) virion-associated transactivator open reading frame 62 protein enhances the infectivity of VZV DNA.

Authors:  M Moriuchi; H Moriuchi; S E Straus; J I Cohen
Journal:  Virology       Date:  1994-04       Impact factor: 3.616

8.  Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression.

Authors:  R I Connor; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

9.  Molecular cloning and functional expression of a new human CC-chemokine receptor gene.

Authors:  M Samson; O Labbe; C Mollereau; G Vassart; M Parmentier
Journal:  Biochemistry       Date:  1996-03-19       Impact factor: 3.162

10.  A family of serine proteases expressed exclusively in myelo-monocytic cells specifically processes the nuclear factor-kappa B subunit p65 in vitro and may impair human immunodeficiency virus replication in these cells.

Authors:  G Franzoso; P Biswas; G Poli; L M Carlson; K D Brown; M Tomita-Yamaguchi; A S Fauci; U K Siebenlist
Journal:  J Exp Med       Date:  1994-10-01       Impact factor: 14.307

View more
  11 in total

1.  Mouse-human heterokaryons support efficient human immunodeficiency virus type 1 assembly.

Authors:  R Mariani; B A Rasala; G Rutter; K Wiegers; S M Brandt; H G Kräusslich; N R Landau
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  TRIM22 inhibits HIV-1 transcription independently of its E3 ubiquitin ligase activity, Tat, and NF-kappaB-responsive long terminal repeat elements.

Authors:  Anna Kajaste-Rudnitski; Sara S Marelli; Cinzia Pultrone; Thomas Pertel; Pradeep D Uchil; Nadir Mechti; Walther Mothes; Guido Poli; Jeremy Luban; Elisa Vicenzi
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

3.  1,25-Dihydroxyvitamin D3 upregulates functional CXCR4 human immunodeficiency virus type 1 coreceptors in U937 minus clones: NF-kappaB-independent enhancement of viral replication.

Authors:  P Biswas; M Mengozzi; B Mantelli; F Delfanti; A Brambilla; E Vicenzi; G Poli
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

4.  Cathepsin G, a neutrophil-derived serine protease, increases susceptibility of macrophages to acute human immunodeficiency virus type 1 infection.

Authors:  H Moriuchi; M Moriuchi; A S Fauci
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

5.  Differentiation of promonocytic U937 subclones into macrophagelike phenotypes regulates a cellular factor(s) which modulates fusion/entry of macrophagetropic human immunodeficiency virus type 1.

Authors:  H Moriuchi; M Moriuchi; A S Fauci
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

6.  CXCR4 and CCR5 genetic polymorphisms in long-term nonprogressive human immunodeficiency virus infection: lack of association with mutations other than CCR5-Delta32.

Authors:  O J Cohen; S Paolucci; S M Bende; M Daucher; H Moriuchi; M Moriuchi; C Cicala; R T Davey; B Baird; A S Fauci
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

7.  Enhancement of human immunodeficiency virus type 1 infection by the CC-chemokine RANTES is independent of the mechanism of virus-cell fusion.

Authors:  C J Gordon; M A Muesing; A E Proudfoot; C A Power; J P Moore; A Trkola
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

8.  Intrinsic human immunodeficiency virus type 1 resistance of hematopoietic stem cells despite coreceptor expression.

Authors:  H Shen; T Cheng; F I Preffer; D Dombkowski; M H Tomasson; D E Golan; O Yang; W Hofmann; J G Sodroski; A D Luster; D T Scadden
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

9.  Exposure to bacterial products renders macrophages highly susceptible to T-tropic HIV-1.

Authors:  M Moriuchi; H Moriuchi; W Turner; A S Fauci
Journal:  J Clin Invest       Date:  1998-10-15       Impact factor: 14.808

10.  Cell-type-dependent effect of transforming growth factor beta, a major cytokine in breast milk, on human immunodeficiency virus type 1 infection of mammary epithelial MCF-7 cells or macrophages.

Authors:  Masako Moriuchi; Hiroyuki Moriuchi
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.